Obsidian Therapeutics
Engineered protein therapeutics using proprietary cytoDRiVE platform technology
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2015
- Latest Form D
- $32.4M, Dec 2017
- Total capital
- $32.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $32.4M
- 1 Form D · last Dec 2017
- 107 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 30 pending · first 2021
- Rank in peer group#167 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$32.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#167 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carolyn NgDirectorNamed in SEC Form D filings
- David NeafusExecutive OfficerNamed in SEC Form D filings
- Jason GardnerDirectorNamed in SEC Form D filings
- Karen HongDirectorNamed in SEC Form D filings
- Michael GilmanExecutive Officer, DirectorNamed in SEC Form D filings
- Peter BarrettExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 40- PendingCOMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF RNAiUSPTOApplication 19453178
- GrantedCA2-IL15 Fusion Proteins For Tunable RegulationUSPTOUS 12,642,792
- GrantedCA2 Compositions And Methods For Tunable RegulationUSPTOUS 12,630,599
Show all 40 patent records
- COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF RNAiJul 23, 2026 · Application 19453178Pending
- CA2-IL15 Fusion Proteins For Tunable RegulationJun 2, 2026 · US 12,642,792Granted
- CA2 Compositions And Methods For Tunable RegulationMay 19, 2026 · US 12,630,599Granted
- Low Dose Lymphodepletion With Adoptive Cell TherapyApr 30, 2026 · Application 19374988Pending
- Compositions For Dhfr Tunable Protein RegulationApr 28, 2026 · US 12,612,637Granted
- Compact Drug Responsive Domains For Regulation Of Function/abundance And Delivery Of Polypeptide PayloadsJun 12, 2025 · Application 18843910Pending
- Methods For Identifying And Using Allogeneic Tumor Infiltrating Lymphocytes To Treat CancerMay 1, 2025 · Application 18723120Pending
- Membrane Bound IL12 Compositions And Methods For Tunable RegulationFeb 18, 2025 · US 12,227,551Granted
- Compositions And Systems For Regulation Of Function/abundance And Delivery Of Polypeptide PayloadsDec 26, 2024 · Application 18696810Pending
- Dhfr Tunable Protein RegulationDec 5, 2024 · Application 18787024Pending
- Dhfr Tunable Protein RegulationOct 1, 2024 · US 12,104,178Granted
- Administration Of Tumor Infiltrating Lymphocytes With Membrane Bound Interleukin 15 To Treat CancerApr 25, 2024 · Application 18501621Pending
- Tumor-infiltrating Lymphocytes With Membrane Bound Interleukin 15 And Uses ThereofApr 4, 2024 · Application 18261765Pending
- Compositions And Methods For Expansion Of T Cells And Tumor Infiltrating LymphocytesMar 7, 2024 · Application 18261761Pending
- Regulated Biocircuit SystemsJul 27, 2023 · Application 17888808Pending
- PDE5 Compositions And Methods For ImmunotherapyJun 6, 2023 · US 11,666,642Granted
- Dhfr Tunable Protein RegulationApr 18, 2023 · US 11,629,340Granted
- Tandem CD19 Car-based Compositions And Methods For ImmunotherapyMar 23, 2023 · Application 17753320Pending
- Compositions And Methods For Regulation Of TranscriptionFeb 23, 2023 · Application 17791091Pending
- CA2 Compositions And Methods For Tunable RegulationJan 26, 2023 · Application 17436892Pending
- PDE5 Derived Regulatory Constructs And Methods Of Use In ImmunotherapyDec 22, 2022 · Application 17251635Pending
- Regulated Biocircuit SystemsSep 20, 2022 · US 11,446,398Granted
- CA2 Compositions And Methods For Tunable RegulationAug 18, 2022 · Application 17596281Pending
- CD40L Compositions And Methods For Tunable RegulationJun 9, 2022 · Application 17436997Pending
- Compositions And Methods For Tunable Regulation Of Cas NucleasesJun 2, 2022 · Application 17548076Pending
- Administration Of Tumor Infiltrating Lymphocytes With Membrane Bound Interleukin 15 To Treat CancerMay 5, 2022 · Application 17577940Pending
- PDE5 Compositions And Methods For ImmunotherapyFeb 8, 2022 · US 11,241,485Granted
- Er Tunable Protein RegulationDec 16, 2021 · Application 17288373Pending
- CA2 Compositions And Methods For Tunable RegulationJul 13, 2021 · US 11,058,725Granted
- Methods For Identifying And Using Allogeneic Tumor Infiltrating Lymphocytes To Treat CancerApplication 63266892Pending
- COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF RNAiApplication 63747704Pending
- COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF RNAiApplication 63839528Pending
- Compact Drug Responsive Domains For Regulation Of Function/abundance And Delivery Of Polypeptide PayloadsApplication PCTUS2023064612Pending
- Compositions And Methods For Tunable Regulation Of RnaiApplication PCTUS2026011795Pending
- Compositions And Methods For Tunable Regulation Of IL15 And LightApplication PCTUS2024061902Pending
- Compositions And Methods For Enhanced Payload Regulation Using Nuclear Factor Of Activated T Cells (nfat) Response ElementsApplication 63607998Pending
- Compact Drug Responsive Domains For Regulation Of Function/abundance And Delivery Of Polypeptide PayloadsApplication 63269582Pending
- Compositions And Methods For Expression Of Anti-bcma Chimeric Antigen Receptors With Small Molecule-regulated IL15 In T CellsApplication PCTUS2021050420Pending
- Compositions And Systems For Regulation Of Function/abundance And Delivery Of Polypeptide PayloadsApplication 63342443Pending
- Compositions And Methods For Tunable Regulation Of IL15 And LightApplication 63615149Pending
Related companies, and why
- Korro BioSimilar federal contract value in Biotech · null in contracts
- Altis LabsSimilar federal contract value in Biotech · null in contracts
- Matchpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SUNNYLIFE PHARMA INC.Similar federal contract value in Biotech · null in contracts
- Remix TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Renasant BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .